On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Hôpital Cardiologique du Haut-Lévêque

InstitutionResearch output, impact & collaborations

Hôpital Cardiologique du Haut-Lévêque is a institution indexed in ScholarIQ from OpenAlex.

What is known about Hôpital Cardiologique du Haut-Lévêque?

ScholarIQrecord summary

Hôpital Cardiologique du Haut-Lévêque is a research organisation in Pessac, FR. OpenAlex records 9,375 works and 1,098,382 citations for it. 1,739 researchers list it as their most recent affiliation.

How many works does Hôpital Cardiologique du Haut-Lévêque have?

ScholarIQindexed works

Hôpital Cardiologique du Haut-Lévêque has 9,375 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Hôpital Cardiologique du Haut-Lévêque have?

ScholarIQcitation count

Hôpital Cardiologique du Haut-Lévêque has 1,098,382 citations in the OpenAlex counts ScholarIQ stores.

How many researchers are at Hôpital Cardiologique du Haut-Lévêque?

ScholarIQresearcher count

Hôpital Cardiologique du Haut-Lévêque has 1,739 researchers in the ScholarIQ index.

What is the average h-index at Hôpital Cardiologique du Haut-Lévêque?

ScholarIQavg h-index

Hôpital Cardiologique du Haut-Lévêque has an average h-index of 64 in OpenAlex.

What is the ROR of Hôpital Cardiologique du Haut-Lévêque?

ScholarIQror

The ROR for Hôpital Cardiologique du Haut-Lévêque is on the source record.

What is the OpenAlex record for Hôpital Cardiologique du Haut-Lévêque?

ScholarIQopenalex

The OpenAlex for Hôpital Cardiologique du Haut-Lévêque is on the source record.

Who are the most-cited researchers behind Hôpital Cardiologique du Haut-Lévêque?

ScholarIQtop researchers by citations
1
Jean‐Frédéric Blanc · Hepatocellular Carcinoma Treatment and Prognosis
338 works18,904 citations

What are the most-cited papers on Hôpital Cardiologique du Haut-Lévêque?

ScholarIQmost cited works
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
The Lancet Oncology. 20182,547 Citations
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
Masatoshi Kudo, Guohong Han, Richard S. Finn, Ronnie T.P. Poon, Jean‐Frédéric Blanc, Lünan Yan, Jijin Yang, Ligong Lu, Won Young Tak, Xiaoping Yu, Joon-Hyeok Lee, Shi‐Ming Lin, Changping Wu, Tawesak Tanwandee, Guoliang Shao, Ian Walters, Christine Dela Cruz, Valerie Poulart, Jianhua Wang
Hepatology. 2014352 Citations
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, John F. Kurland, Alejandra Negro, Ghassan K. Abou‐Alfa, Sérgio Santos de Azevêdo, Maria Ignez Braghiroli, Gustavo Girotto, Arinilda Campos Bragagnoli, Ricardo Branco, Adilson Faccio, Andrea Moretto, Nils Gunnar Skare, Jamille Dutra, Luciana Viola, Karina Vianna, Fernando Meton, Cláudia Vaz de Melo Sette, Amanda Faulhaber, Vincent C. Tam, Félix Couture, Jim Biagi, Hélène Castel, Karen Mulder, Yoo‐Joung Ko, Kevin Zbuk, Stephen Welch, Annie Beaudoin, Alexandra Heurgué, Éric Assenat, Isabelle Archambeaud, David Tougeron, Jean‐Marie Péron, Marine Gilabert, Jean–Pierre Bronowicki, Stéphane Cattan, Jean‐Frédéric Blanc, Mohamed Bouattour, Jean–Marc Phelip, Valérie Boige, Pierre Michel, Anne-Claire Frin, Enrico N. De Toni, Marie‐Luise Berres, Arndt Vogel, Thomas Berg, Thomas J. Ettrich, Dirk Waldschmidt, H. Wedemeyer, Marcus‐Alexander Wörns, Michael Bitzer, Karl-Heinz Weiss, George Lau, Stephen L. Chan, Thomas Yau, Y. Tai, Ann Shing Lee, Satheesh Chiradoni Thungappa, Lokesh K. N, Vikas Sureshchand Ostwal, Kattimani Kiran Ashok, Sushant Mittal, Hari Om Goyal, Sankar Srinivasan, Ghanashyam Biswas, Mallavarapu Mohan, Sewanti Limaye, Nirav Asarawala, Lorenza Rimassa, Alfredo Falcone, Luca Gianni, Antonio Gasbarrini, Bruno Daniele, Antonio Avallone, Giovanni Luca Frassineti, Fausto Roila, Masatoshi Kudo, Tomokazu Kawaoka, Manabu Morimoto, Yasuhiro Takikawa
Annals of Oncology. 2024326 CitationsOPEN ACCESS
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro, Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L. Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Valeriy V Breder, Tanita Suttichaimongkol, Mohamed Bouattour, Shi-Ming Lin, Jean-Marie Peron, Quang T Nguyen, Lünan Yan, Chang-Fang Chiu, Florinda A Santos, Anil Veluvolu, Satheesh Chiradoni Thungappa, Marco Matos, Magdalena Żotkiewicz, Stephanie I. Udoye, John F. Kurland, G. Cohen, Riccardo Lencioni, Kathia Cristina Abdalla, Manon Allaire, Gustavo R. Alves, Luís Carlos Moreira Antunes, Eric Assénat, Sérgio Jobim Azevedo, Rafael Barreto, Muhammad Shaalan Beg, Glaucio Bertollo, Jean‐Frédéric Blanc, Mohamed Bouattour, Rakesh Reddy Boya, Valery Breder, Jean–Pierre Bronowicki, Manoch Buranachokphaisan, Adam M. Burgoyne, Stephen L. Chan, Ting‐Tsung Chang, Yee Chao, Eric Chen, Xiaoming Chen, Chang-Fang Chiu, Minsig Choi, SUNGHEE CHOI, Natalie G. Coburn, Luis Contreras, Farshid Dayyani, Thomas Decaens, Arunee Dechaphunkul, Maria del Consuelo Diaz, Anouk Dev, Jamille Dutra, Melissa Eastgate, Jose Escobar, Bassam Estfan, Vittorio Ferrari, Anne-Claire Frin, Sandip Ganguly, Ranga Raman Ganta, Shanzhi Gu, Yabing Guo, Atsushi Hagihara, Jeong Heo, Chih‐Hung Hsu, Jimmy Hwang, Yoshitaka Inaba, Shikha Jain, D. Jonker, Shruti Kate, Shruti Kate, Naoya Kato, Tomokazu Kawaoka, Kwong‐Ming Kee, Seung Up Kim, Kiyohide Kioka, Hironori Koga, Masatoshi Kudo, Hidekatsu Kuroda, Phuong Uyen Le, Han-chu Lee, Joon Hyeok Lee, Teng-Yu Lee, Dongliang Li, Hailiang Li, Wei Li, Xiao Li, Cheng-Yao Lin, Shi-Ming Lin, Yamil Lopez
The Lancet. 2025263 CitationsOPEN ACCESS

How much of the research on Hôpital Cardiologique du Haut-Lévêque is open access?

ScholarIQopen access share
50%OPEN ACCESS
Gold
0%
Green
25%
Hybrid
25%
Bronze
0%
Closed
50%

Related on ScholarIQ

470M+ articles · 14-day free trial